Showing results (21-30 of 60) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignanciesRanjana H Advani, Joseph J Buggy, Jeff P Sharman, et al.
Haematologica|October 12, 2019
Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphomaPaolo Strati, Mohamed Amin Ahmed, Nathan H Fowler, et al.
British Journal of Haematology|March 29, 2019
Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trialMelody R Becnel, Loretta J Nastoupil, Felipe Samaniego, et al.
Blood Advances|January 11, 2022
Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphomaLoretta J Nastoupil, Collin K Chin, Jason R Westin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2021
RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell LymphomaPier Luigi Zinzani, Thomas Rodgers, Dario Marino, et al.
The Lancet. Haematology|February 3, 2019
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trialLoretta J Nastoupil, Matthew A Lunning, Julie M Vose, et al.
British Journal of Haematology|March 25, 2017
High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized StudyLoretta J Nastoupil, Peter McLaughlin, Lei Feng, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 29, 2019
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell LymphomaStefan K Barta, Jasmine Zain, Alexander W MacFarlane, et al.
British Journal of Haematology|March 18, 2020
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphomaNathan H Fowler, Loretta Nastoupil, Sven De Vos, et al.
Blood Advances|January 4, 2018
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphomaSven de Vos, Nina D Wagner-Johnston, Steven E Coutre, et al.
Pageof 6